Importance of high radiation doses (72 Gy or greater) in the treatment of Stage T1-T3 adenocarcinoma of the prostate

Urology

Volumn 55, Issue 1, 2000, Pages 85-90

  Lyons, Janice A ^a   Kupelian, Patrick A ^a   Mohan, Dasarahally S ^a   Reddy, Chandana A ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BIOPSY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; TREATMENT OUTCOME;

ADENOCARCINOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 0033954427     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00380-5     Document Type: Article

References (18)

1. Kupelian P.A. Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses preliminary results . J Urol. 161:1999;386.
2. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 5:1999;152-158.
3. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
4. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
5. Pollack A., Zagars G., Starkshall G., et al. Conventional vs. conformal radiotherapy for prostate cancer preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;555-564.
6. Katcher J., Kupelian P.A., Zippe C., et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 37:1997;871-876.
7. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
8. Pollack A., Zagars G.K. External beam radiotherapy for stage T1/T2 prostate cancer how does it stack up? Urology. 51:1998;258-264.
9. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
10. Pilepich M., Krall J., Al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma a randomized comparative trial of the RTOG . Urology. 45:1995;616-623.
11. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of Radiation Therapy Oncology Group Protocol 85-31 . J Clin Oncol. 15:1997;1013-1021.
12. Pollack A., Zagars G.K. Androgen ablation in addition to radiation therapy for prostate cancer is there true benefit? Semin Radiat Oncol. 8:1998;95-106.
13. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
14. MacKay R.I., Hendry J.H., Moore C.J., et al. Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms. Br J Radiol. 70:1997;517-526.
15. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer further evidence for a significant dose effect . Int J Radiat Oncol Biol Phys. 35:1996;251-257. (see comments).
16. Sandler H.M., McLaughlin P.W., Ten Haken R.K., et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer low risk of chronic rectal morbidity observed in a large series of patients . Int J Radiat Oncol Biol Phys. 33:1995;797-801.
17. Hanlon A.L., Schultheiss T.E., Hunt M.A., et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys. 38:1997;59-63.
18. Nguyen L.N., Pollack A., Zagars G.K. Late effects after radiotherapy for prostate cancer in a randomized dose-response study results of a self-assessment questionnaire . Urology. 51:1998;991-997.